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Abstract
Background: Resistin, secreted from adipocytes, causes insulin resistance in mice. The relationship between resistin and
coronary artery disease is highly controversial, and the information regarding resistin and ischemic stroke is limited. In the
present study, the association between serum resistin concentration and cardiovascular disease (CVD) was investigated in a
general Japanese population.
Methods: A total of 3,201 community-dwelling individuals aged 40 years or older (1,382 men and 1,819 women) were divided
into quintiles of serum resistin, and the association between resistin and CVD was examined cross-sectionally. The combined
effect of either diabetes or hypertension and high serum resistin was also assessed. Serum resistin was measured using ELISA.
Results: Compared to those without CVD, age- and sex-adjusted mean serum resistin concentrations were greater in subjects
with CVD (p = 0.002) or ischemic stroke (p < 0.001), especially in those with lacunar and atherothrombotic infarction, but not
elevated in subjects with hemorrhagic stroke or coronary heart disease. When analyzed by quintile of serum resistin
concentration, the age- and sex-adjusted odds ratio (OR) for having CVD and ischemic stroke increased with quintile of serum
resistin (p for trends, 0.02 for CVD, < 0.001 for ischemic stroke), while such associations were not observed for hemorrhagic
stroke or coronary heart disease. Compared to the first quintile, the age- and sex-adjusted OR of ischemic stroke was greater
in the third (OR = 3.54; 95% confidence interval [CI], 1.17-10.67; p = 0.02), fourth (OR = 4.48; 95% CI, 1.53-13.09; p = 0.006),
and fifth quintiles (OR = 4.70; 95% CI, 1.62-13.61; p = 0.004). These associations remained substantially unchanged even after
adjustment for other confounding factors including high-sensitivity C-reactive protein. In the stratified analysis, the combination
of high serum resistin and either diabetes or hypertension markedly increased the risk of ischemic stroke.
Conclusion: Elevated serum resistin concentration appears to be an independent risk factor for ischemic stroke, especially
lacunar and atherothrombotic infarction in the general Japanese population. The combination of high resistin and the presence
of either diabetes or hypertension increased the risk of ischemic stroke.
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Background
Resistin belongs to a family of cysteine-rich secretory pro-
teins called resistin-like molecules [1]. In rodents, resistin
is derived almost exclusively from adipose tissue, and
serum resistin is elevated in animal models of obesity and
insulin resistance [2-4]. On the other hand, in humans,
monocytes and macrophages express resistin at high levels
[5]; thus, the pathophysiological role of resistin may differ
between species. In vitro, resistin activates human
endothelial cells, leading to increased expression of adhe-
sion molecules, and induces human aortic muscle cell
proliferation [6,7]. Furthermore, several clinical and epi-
demiological studies have revealed positive associations
between plasma concentrations of resistin and proinflam-
matory cytokines [8-10], which are emerging risk factors
for cardiovascular disease (CVD). These findings suggest
that resistin contributes to the development of atheroscle-
rosis and thereby is linked to clinical vascular events.
However, the relationship between resistin and coronary
artery disease is highly controversial [11-14]. Further-
more, the information regarding resistin and ischemic
stroke in general population is limited to only one epide-
miological study that reported no association between cir-
culating resistin and ischemic stroke [14].
The aim of the present study was to examine the associa-
tion between serum resistin and CVD in a cross-sectional
study of a defined Japanese population, taking into
account a comprehensive list of risk factors, including
high-sensitivity C-reactive protein (hs-CRP). Our findings
suggest that elevated serum resistin concentration is a sig-
nificant risk factor for ischemic stroke in a general Japa-
nese population.
Methods
Study population
In 2002, a screening survey for the present study was per-
formed in the town of Hisayama, a suburb of the Fukuoka
metropolitan area in Japan. The age and occupational dis-
tributions and nutrient intake of the population were
almost identical to those of Japan as a whole based on
data from the national census and nutrition survey. A
detailed description of this survey was published previ-
ously [15]. Briefly, of all residents aged 40 years or over,
3,328 underwent the examination (participation rate,
77.6%). After excluding 30 subjects who did not consent
to participate in the study, 86 who had already eaten
breakfast, and 11 who did not have enough stored sera
with which to measure resistin concentrations, a total of
3,201 (1,382 men and 1,819 women) were enrolled in
the study group and underwent a comprehensive assess-
ment. This study was approved by the Ethics Committee
of Kyushu University, and written informed consent was
obtained from all participants.
Definition of cardiovascular disease
Cases of CVD were defined as subjects who had histories
of stroke or coronary heart disease. CVD was identified
using the following criteria. The diagnosis and classifica-
tion of stroke were determined on the basis of clinical
information, including brain computed tomography and
magnetic resonance imaging, cerebral angiography,
echocardiography or carotid duplex imaging. Stroke was
defined as sudden onset of nonconvulsive and focal neu-
rological deficit persisting for ≥24 hours and was classified
as either ischemic or hemorrhagic [16,17]. Hemorrhagic
stroke included brain hemorrhage and subarachnoid
hemorrhage. Ischemic stroke was further divided into 4
clinical categories -- lacunar infarction, atherothrombotic
infarction, cardioembolic infarction, and undetermined
subtype of ischemic stroke -- based on the Classification
of Cerebrovascular Disease III proposed by the National
Institute of Neurological Disorders and Stroke [18], as
well as on the basis of the diagnostic criteria of the Trial of
Org10172 in Acute Stroke Treatment Study [19] and the
Cerebral Embolism Task Force [20]. Details of the diag-
nostic criteria for the ischemic stroke subtypes have been
described previously [21]. In brief, lacunar infarction was
defined as the presence of a relevant brainstem, basal gan-
glia, or subcortical hemispheric lesion with a diameter of
< 1.5 cm demonstrated by brain imaging, and no evidence
of cerebral cortical or cerebellar impairment. Athero-
thrombotic infarction was diagnosed when the subjects
had significant stenosis (> 50%) or occlusion of a major
cerebral artery with an infarct ≥1.5 cm in a brain imaging
study. The diagnosis of cardioembolic infarction was
made on the basis of primary and secondary clinical fea-
tures suggestive of cardioembolic infarction as reported by
the Cerebral Embolism Task Force [20]. The undeter-
mined subtype of ischemic stroke included strokes that
could not be classified because of insufficient clinical or
morphologic information. We considered morphologic
findings to be significant and used clinical features as ref-
erence information. Cases of cerebrovascular diseases that
could be attributed to a distinct pathology, such as colla-
gen disease, hematological disorder, trauma, chronic sub-
dural hematoma, or moyamoya disease, were excluded
from the evaluation.
The diagnostic criteria for coronary heart disease included
acute myocardial infarction, silent myocardial infarction
or coronary artery disease followed by coronary artery
bypass surgery or angioplasty [16,17]. Acute myocardial
infarction was diagnosed when a subject met at least two
of the following criteria: (1) typical symptoms, including
prolonged severe anterior chest pain; (2) abnormal eleva-
tion in cardiac enzymes, i.e., greater than a two-fold
increase in the upper limit of the normal range; (3) evolv-
ing diagnostic electrocardiogram (ECG) changes; and, (4)
morphological changes, including local asynergy of car-Cardiovascular Diabetology 2009, 8:60 http://www.cardiab.com/content/8/1/60
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diac wall motion on echocardiography or persistent per-
fusion defects observed using cardiac scintigraphy. Silent
myocardial infarction was defined as the above-men-
tioned morphological changes without any history of
clinical symptoms or abnormalities in cardiac enzymes.
Among the participants, 175 subjects had a history of
CVD as follows: 79 had ischemic stroke; 41 had hemor-
rhagic stroke; 42 had coronary heart disease; 11 had both
ischemic stroke and coronary heart disease; and, 2 had
hemorrhagic stroke and coronary heart disease. In the
analysis stratified by type of CVD, coexisting CVDs were
each stratified into their respective types. Furthermore, on
the basis of the above criteria, 90 ischemic stroke cases
were divided into 51 cases of lacunar infarction, 29 of
atherothrombotic infarction, 7 of cardioembolic infarc-
tion, and 3 of undetermined infarction; 43 hemorrhagic
stroke cases were divided into 31 of brain hemorrhage and
12 of subarachnoid hemorrhage.
Measurement of serum resistin concentrations
At the screening examination, blood samples were
obtained between 8:00 and 10:30 AM after at least a 12-
hour overnight fast. An aliquot of serum from each subject
was stored at -80°C. Serum resistin was measured using a
human ELISA kit (R&D Systems, Inc., Minneapolis, MN)
following the manufacturer's protocol. According to data
supplied by the manufacturer, the limit of detection was
0.16 ng/ml, and the intra-assay coefficient of variations
(CVs) were < 5% for low concentrations, and < 4% for
high concentrations. The inter-assay CV was < 9% for both
low and high concentrations. Recovery was greater than
90%. We confirmed that linearity was maintained at con-
centrations less than 0.16 ng/ml, and both intra- and
inter-assay CVs were comparable to those specified by the
manufacturer (2.6-10.5%). The antibodies used in the
enzyme-linked immunosorbent assay (ELISA) do not
cross-react with either mouse resistin or other human
cytokines. The results obtained using the ELISA manufac-
tured by R&D were highly correlated with those obtained
previously using a kit supplied by LINCO (Linco
Research, Inc., St. Charles, MO) (r = 0.987, y =
1.040x+0.469, y, this kit, x, LINCO's kit) [22-24].
Measurement of confounding factors
Blood for the glucose assay was collected into tubes con-
taining NaF, and plasma glucose concentrations were
determined immediately after venipuncture using the glu-
cose-oxidase method. Serum total cholesterol and high
density lipoprotein (HDL) cholesterol concentrations
were determined enzymatically. hs-CRP concentrations
were measured using a modification of the Behring Latex-
Enhanced CRP assay on a Behring Nephelometer BN-100
(Behring Diagnostics, Westwood, MA). Blood pressure
was measured three times using a standard mercury
sphygmomanometer in the seated position after the sub-
ject had rested for at least 5 minutes. ECG abnormalities
were defined as left ventricular hypertrophy (Minnesota
Code 3-1) and/or ST depression (Minnesota Code 4-1, 2,
3).
Body height and weight were measured in light clothing
without shoes, and body mass index (BMI) was calcu-
lated. Each participant completed a self-administered
questionnaire that assessed medical history, smoking
habits, alcohol intake, and exercise. The questionnaire
was checked by trained interviewers at the screening. Alco-
hol intake and smoking habits were classified as either
presence or absence of current habitual use. Those sub-
jects who engaged in sports or other forms of exercise ≥3
times a week during their leisure time categorized regular
exercisers.
Statistical analysis
The SAS software package version 8.2 (SAS Institute, Inc.,
Cary, NC) was used to perform all statistical analyses. The
subjects were divided into quintiles of resistin concentra-
tion as follows: < 6.8, 6.8 to 8.7, 8.8 to 11.5, 11.6 to 16.2,
and  ≥16.3 ng/ml. Values of possible risk factors were
adjusted for age and sex using the covariance method and
were compared among the quintiles using the linear
regression model. Age- and sex-adjusted resistin concen-
trations were compared among CVD subtypes using the
same methods. The frequencies of risk factors were
adjusted for age and sex by the direct method using all
subjects as a standard population and were tested for
trends using the Cochran-Mantel-Haenszel test. Age- and
sex-adjusted or multivariate-adjusted odds ratios (ORs)
and 95% confidence intervals (CIs) for CVD were calcu-
lated using logistic regression analysis. A p-value < 0.05
was considered statistically significant in all analyses.
Results
Clinical characteristics of subjects
Age- and sex-adjusted means or frequencies of potential
risk factors by quintiles of serum resistin concentration
are shown in Table 1. Age and hs-CRP, and the frequency
of male sex increased with quintiles of resistin, while
mean HDL-cholesterol and the frequencies of alcohol
consumption and regular exercise were negatively associ-
ated with the quintiles of resistin. The other variables were
not significantly associated with resistin quintiles.
Serum resistin concentrations by cardiovascular disease
Age- and sex-adjusted serum resistin concentrations were
greater in subjects with total CVD than in those without
CVD (p = 0.002) (Table 2). When CVD was divided into
types, subjects with ischemic stroke had greater resistin
concentrations than those without CVD (p < 0.001).
Regarding subtypes of ischemic stroke, subjects with lacu-
nar and atherothrombotic infarction had greater resistinCardiovascular Diabetology 2009, 8:60 http://www.cardiab.com/content/8/1/60
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Table 1: Age- and sex-adjusted means or frequencies of cardiovascular risk factors according to serum resistin quintiles.
Serum resistin level (ng/ml)
1.5-6.7 6.8-8.7 8.8-11.5 11.6-16.2 16.3-90.2
Variables (n = 648) (n = 633) (n = 641) (n = 636) (n = 643) P value for trend
Age (years) 59
(11)
61
(12)
61
(12)
62
(13)
64
(14)
< 0.001
Men (%) 39.2 38.7 40.6 46.2 51.2 < 0.001
BMI (kg/m2)2 3 . 1
(3.4)
23.2
(3.4)
22.9
(3.4)
23.1
(3.4)
23.1
(3.4)
0.69
Fasting plasma glucose (mmol/l) 6.1
(1.3)
6.1
(1.3)
6.0
(1.3)
6.1
(1.3)
6.0
(1.3)
0.55
Diabetes (%) 13.7 13.8 11.2 14.8 14.3 0.82
Total cholesterol (mmol/l) 5.25
(0.89)
5.22
(0.89)
5.27
(0.89)
5.27
(0.89)
5.19
(0.90)
0.51
HDL-cholesterol (mmol/l) 1.70
(0.40)
1.61
(0.39)
1.60
(0.39)
1.60
(0.39)
1.53
(0.40)
< 0.001
High sensitivity C-reactive protein (mg/l) 0.43
(0.04-4.53)
0.49
(0.05-5.06)
0.54
(0.05-5.53)
0.55
(0.05-5.64)
0.68
(0.07-7.18)
< 0.001
Systolic blood pressure (mmHg) 132
(20)
133
(20)
131
(20)
132
(20)
132
(20)
0.65
Diastolic blood pressure (mmHg) 79
(12)
79
(12)
78
(12)
79
(12)
78
(12)
0.38
Antihypertensive medication (%) 21.7 28.2 22.1 22.8 26.2 0.52
H y p e r t e n s i o n  ( % ) 4 4 . 44 6 . 63 9 . 64 3 . 64 7 . 2 0 . 6 7
Electrocardiographic abnormalities (%) 15.1 16.1 15.8 14.9 16.1 0.47
Current drinking (%) 50.9 45.1 40.8 42.1 37.1 < 0.001
C u r r e n t  s m o k i n g  ( % ) 2 0 . 92 0 . 22 2 . 72 0 . 32 4 . 7 0 . 1 4
Regular exercise (%) 11.6 11.0 10.8 8.4 9.5 0.04
BMI: body mass index; HDL: high density lipoprotein. All values are given as mean (standard deviation) or as percentages.
C-reactive protein is shown by geometric mean and 95% confidence intervals due to the skewed distribution. Age and percent of men are not 
adjusted.
Table 2: Age- and sex-adjusted resistin values according to types of cardiovascular disease.
Number Age- and sex-
adjusted resistin 
values (ng/ml)
P vs. no cardiovascular disease cases
No cardiovascular disease 3,026 10.3 (3.8-28.0) -
Cardiovascular disease 175 11.7 (4.2-32.4) 0.002
Ischemic stroke 90 13.0 (4.7-35.7) < 0.001
Lacunar infarction 51 12.1 (4.4-32.9) 0.02
Atherothrombotic infarction 29 16.3 (6.0-44.4) < 0.001
Cardioembolic infarction 7 11.5 (4.2-31.0) 0.55
Undetermined infarction 3 6.7 (1.7-18.0) 0.14
Hemorrhagic stroke 43 10.3 (3.8-28.1) 0.90
Brain hemorrhage 31 11.1 (4.1-30.2) 0.37
Subarachnoid hemorrhage 12 8.6 (3.2-23.2) 0.22
Coronary heart disease 55 11.3 (4.1-31.0) 0.14
Resistin is shown by geometric mean and 95% confidenceintervals due to the skewed distribution.Cardiovascular Diabetology 2009, 8:60 http://www.cardiab.com/content/8/1/60
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than subjects without CVD (p = 0.02 for lacunar infarc-
tion; p < 0.001 for atherothrombotic infarction); how-
ever, no association was observed between resistin and
cardioembolic infarction or undetermined subtype of
ischemic stroke. Resistin concentrations in subjects with
hemorrhagic stroke, including brain and subarachnoid
hemorrhage, and coronary heart disease were not differ-
ent from subjects without CVD.
Association of resistin concentrations with cardiovascular 
disease
To further evaluate the association between serum resistin
concentrations and the risk of CVD, age- and sex-adjusted
or multivariate-adjusted ORs were estimated by quintiles
of resistin concentration (Table 3). In Model 1, the age-
and sex-adjusted ORs for total CVD and ischemic stroke
increased with quintile of serum resistin (p for trends,
0.02 for CVD, < 0.001 for ischemic stroke). Compared to
the first quintile, the age- and sex-adjusted OR for
ischemic stroke was greater in the third, fourth, and fifth
quintiles (the third quintile: OR 3.54, 95%CI 1.17-10.67,
p = 0.02; the fourth quintile: OR 4.48, 95%CI 1.53-13.09,
p = 0.006; the fifth quintile: OR 4.70, 95%CI 1.62-13.61,
p = 0.004), while there was no association between quin-
tile of resistin and CVD. The association between quintile
of resistin and ischemic stroke remained significant even
after adjustment for age, sex, BMI, diabetes, total choles-
terol, HDL-cholesterol, systolic blood pressure, ECG
abnormalities, current drinking, current smoking, and
regular exercise (Model 2). Furthermore, as shown in
Model 3, after adjustment for hs-CRP and the confound-
ing factors, this association remained essentially
unchanged (Fig. 1). No significant associations were
found between quintile of resistin and either hemorrhagic
stroke or coronary heart disease.
Combined effects of high serum resistin with other risk 
factors
To determine whether high serum resistin concentration
was associated with increased risk of ischemic stroke in
subjects who had either diabetes or hypertension, we
examined the combined and unique effects of high resis-
Table 3: Age- and sex- or multivariate-adjusted odds ratios for cardiovascular diseases according to serum resistin quintiles.
Serum resistin level (ng/ml)
1.5-6.7 6.8-8.7 8.8-11.5 11.6-16.2 16.3-90.2 P value for trend
No cardiovascular disease, n 628 610 604 595 589
Cardiovascular disease, n 20 23 37 41 54
Model 1-adjusted OR (95% CI) 1
(referent)
0.95
(0.51-1.76)
1.55
(0.88-2.74)
1.51
(0.86-2.64)
1.64
(0.95-2.84)
0.02
Model 2-adjusted OR (95% CI) 1
(referent)
0.88
(0.47-1.66)
1.56
(0.88-2.77)
1.39
(0.79-2.45)
1.52
(0.87-2.66)
0.04
Model 3-adjusted OR (95% CI) 1
(referent)
0.87
(0.46-1.63)
1.53
(0.86-2.72)
1.36
(0.77-2.41)
1.47
(0.84-2.58)
0.06
Ischemic stroke, n 4 11 17 25 33
Model 1-adjusted OR (95% CI) 1
(referent)
2.21
(0.70-7.05)
3.54
(1.17-10.67)
4.48
(1.53-13.09)
4.70
(1.62-13.61)
< 0.001
Model 2-adjusted OR (95% CI) 1
(referent)
1.94
(0.60-6.23)
3.36
(1.11-10.22)
3.87
(1.31-11.39)
3.97
(1.36-11.61)
0.002
Model 3-adjusted OR (95% CI) 1
(referent)
1.84
(0.57-5.96)
3.26
(1.07-9.92)
3.66
(1.24-10.79)
3.59
(1.22-10.55)
0.006
Hemorrhagic stroke, n 9 7 9 7 11
Model 1-adjusted OR (95% CI) 1
(referent)
0.70
(0.26-1.92)
0.93
(0.36-2.37)
0.66
(0.24-1.80)
0.89
(0.36-2.23)
0.83
Model 2-adjusted OR (95% CI) 1
(referent)
0.70
(0.26-1.92)
1.02
(0.39-2.64)
0.70
(0.25-1.93)
0.98
(0.38-2.50)
0.99
Model 3-adjusted OR (95% CI) 1
(referent)
0.69
(0.25-1.90)
1.00
(0.39-2.60)
0.69
(0.25-1.90)
0.96
(0.37-2.46)
0.97
Coronary heart disease, n 9 6 12 11 17
Model 1-adjusted OR (95% CI) 1
(referent)
0.55
(0.19-1.57)
1.13
(0.47-2.73)
0.88
(0.36-2.18)
1.11
(0.48-2.59)
0.48
Model 2-adjusted OR (95% CI) 1
(referent)
0.48
(0.16-1.41)
1.20
(0.49-2.95)
0.79
(0.31-1.99)
1.05
(0.44-2.50)
0.53
Model 3-adjusted OR (95% CI) 1
(referent)
0.49
(0.17-1.42)
1.21
(0.49-2.97)
0.80
(0.32-2.02)
1.09
(0.45-2.59)
0.49
OR: odds ratio; CI: confidence interval. Model 1: adjustment was made for age and sex; Model 2: adjustment was made for age, sex, body mass 
index, diabetes, total cholesterol, HDL cholesterol, systolic blood pressure, electrocardiographic abnormalities, current drinking, current smoking, 
and regular exercise; Model 3: adjustment was made for the variables used in Model 2 and for high sensitivity C-reactive protein.Cardiovascular Diabetology 2009, 8:60 http://www.cardiab.com/content/8/1/60
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tin and the presence of either diabetes or hypertension on
the risk of ischemic stroke. High resistin was defined as
the third, fourth, and fifth quintile of resistin concentra-
tion. Compared to non-diabetic subjects with low resistin,
the age- and sex-adjusted OR of ischemic stroke was
greater in non-diabetic subjects with high resistin (OR:
2.15; 95% CI: 1.13-4.10; p = 0.02), but not in diabetic
subjects with low resistin (OR: 1.27; 95% CI: 0.35-4.62; p
= 0.72). The risk of ischemic stroke markedly increased in
diabetic subjects with high resistin (OR: 5.88; 95% CI:
2.82-12.26; p < 0.001). Furthermore, diabetic subjects
with high resistin had greater risk of ischemic stroke than
diabetic subjects with low resistin (p < 0.05). Similarly, a
marked increase in the age- and sex-adjusted risk of
ischemic stroke was observed in hypertensive subjects
with high resistin compared with normotensive subjects
with low resistin (OR: 4.66; 95% CI: 1.81-11.97; p =
0.001), but not in normotensive subjects with high resis-
tin (OR: 1.87; 95%CI: 0.69-5.10; p = 0.22), or hyperten-
sive subjects with low resistin (OR: 1.52; 95%CI: 0.51-
4.54; p = 0.45). In hypertensive subjects, high resistin was
associated with risk of ischemic stroke (p < 0.05). These
associations remained robust even after adjustment for
the above-mentioned confounding factors (Fig. 2).
Discussion
Our large cross-sectional data set representative of the
general Japanese population demonstrated that serum
resistin concentrations were greater in subjects with
ischemic stroke, especially in those with lacunar and
atherothrombotic infarction. Elevated resistin was an
independent risk factor for ischemic stroke even after
adjustment for confounding factors including hs-CRP. In
the stratified analyses, the combination of high resistin
and either diabetes or hypertension markedly increased
the risk of ischemic stroke.
In our study, subjects with lacunar and atherothrombotic
infarction, but not cardioembolic infarction, had greater
resistin concentrations. In particular, in subjects who had
suffered atherothrombotic infarction, serum resistin was
dramatically elevated. Atherothrombotic infarction is
caused by atherosclerotic lesions of large vessels, while
lacunar infarcts occur as a result of multiple mechanisms:
1) lipohyalinosis and/or fibrinoid necrosis; 2) microath-
eroma; 3) atherosclerosis of the basilar and middle cere-
bral artery stem or proximal division of large vessels; or, 4)
cardioembolic occlusion [25]. Lipohyalinosis is a vascu-
lopathy caused by hypertension [25]. In contrast, large
vessel atherosclerosis is associated with traditional risk
factors and inflammation, while cardioembolism seems
less related to atherosclerosis. Thus, our findings regard-
ing the association between each subtype of ischemic
stroke and serum resistin is reasonably consistent with the
Multivariate-adjusted odds ratio for the presence of ischemic  stroke according to quintiles of serum resistin concentra- tions Figure 1
Multivariate-adjusted odds ratio for the presence of 
ischemic stroke according to quintiles of serum resis-
tin concentrations. The OR compared to the first quintile 
is shown. Multivariate adjustment was made for age, sex, 
body mass index, diabetes, total cholesterol, high density 
lipoprotein cholesterol, high sensitivity C-reactive protein, 
systolic blood pressure, electrocardiographic abnormalities, 
current drinking, current smoking and regular exercise. *, p < 
0.05 compared to the first quartile.
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Resistin  (ng/ml)
3
p for trend = 0.006
Multivariate-adjusted odds ratios for ischemic stroke accord- ing to the presence or absence of high serum resistin con- centrations and either diabetes or hypertension Figure 2
Multivariate-adjusted odds ratios for ischemic stroke 
according to the presence or absence of high serum 
resistin concentrations and either diabetes or hyper-
tension. Multivariate adjustment was made as described in 
the legend of Fig. 1, but each risk factor that had been used 
for categorization was excluded from the confounding fac-
tors. High resistin was defined as the third, fourth, and fifth 
quintile of resistin concentration. A. Diabetes (DM). The OR 
compared to the reference (DM (-) + low resistin) is shown. 
*, OR = 5.54 (95% CI, 2.60-11.76), p < 0.001 for DM (+) + 
high resistin. OR = 1.87 (95% CI, 0.97-3.59), p = 0.06, for 
DM (-) + high resistin; OR = 1.25 (95% CI, 0.34-4.64), p = 
0.73 for DM (+) + low resistin. †, p < 0.05 compared to DM 
(+) + low resistin. B. Hypertension (HT). OR compared to 
the reference (HT (-) + low resistin) is shown. *, OR=4.46 
(95% CI, 1.71-11.62), p = 0.002 for HT (+) + high resistin. 
OR= 1.47 (95% CI, 0.53-4.08), p = 0.45, for HT (-) + high 
resistin; OR = 1.48 (95% CI, 0.49-4.53), p = 0.49 for HT (+) 
+ low resistin. †, p < 0.05 compared to HT (+) + low resistin.
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known pathology. Most recently, Tsukahara et al. reported
that serum resistin levels in individuals with diabetes who
had a history of stroke were higher than those without in
a case/control study of Japanese [26]. However, a recent
nested case-control epidemiological study of Europeans
showed that elevated resistin concentration was not a pre-
dictor of ischemic stroke [14]. This inconsistency might be
caused by differences in study design and ethnicity.
Although the European study lacked information on
ischemic stroke subtype, in general, the prevalence of car-
dioembolic infarction, which is a potentially fatal disease
and weakly associated with atherosclerosis in brain ves-
sels, may be greater in prospective design than in cross-
sectional design. In addition, Caucasians are at a greater
risk of cardioembolic infarction compared with Japanese
individuals [16,27,28].
The present study showed that the association between
circulating resistin and ischemic stroke was independent
of hs-CRP and other confounding factors. Resistin could
directly stimulate expression of pro-inflammatory
cytokines such as tumor necrosis factor-α, interleukin-6 in
human peripheral blood mononuclear cells [29] and
increase vascular cell adhesion molecule-1 and intracellu-
lar adhesion molecule-1 gene expression in vascular
endothelial cells [7]. A recent clinical study showed that
the association between plasma resistin and monocyte
chemoattractant protein-1 was independent of hs-CRP
and other confounding factors [30]. Therefore, resistin
could potentiate vascular inflammation and atherogene-
sis.
Our previous studies demonstrated that serum resistin
was tightly correlated with a single nucleotide polymor-
phism (SNP) at -420 of the human resistin gene, namely,
resistin was highest in individuals with the G/G genotype,
followed by the C/G and C/C genotypes [22-24]. It was
reported that Japanese individuals with the C/G or G/G
genotypes of SNP-420 were more likely to have had a
stroke than those with the C/C genotype [26]. A clinical
study of Finns found that the G/G genotype was associ-
ated with cerebrovascular disease [31]. Thus, resistin may
directly contribute to ischemic stroke.
In the present study, serum resistin was not associated
with hemorrhagic stroke or coronary heart disease. To our
knowledge, there are no published studies that examined
the relationship between resistin and hemorrhagic stroke.
Regarding coronary heart disease, reported findings have
been highly controversial; some epidemiological and clin-
ical studies showed a significant association between ele-
vated resistin and coronary heart disease [13,14], whereas,
in other studies, this association was not observed
[11,12]. Further investigations, especially those involving
a larger number of samples, are necessary to clarify the
role of resistin in the development of hemorrhagic stroke
and coronary artery disease.
The present study has three limitations that should be
mentioned. First, due to the cross-sectional design, we
cannot exclude the possibility that hyperresistinemia was
a consequence of ischemic stroke. Prospective studies are
required to address this critical question. Second, the
number of subjects with ischemic stroke was relatively
small, although we used a highly accurate method of
detecting and classifying all cases. Likewise, the lack of
association between either hemorrhagic stroke or coro-
nary heart disease and serum resistin may be reflection of
the small samples. Third, since hemorrhagic stroke and
coronary heart disease both have high mortality, survival
bias could partly explain why no association was found
between these diseases and serum resistin. Thus, the gen-
eralizability of the study results may be somewhat limited.
Conclusion
Serum resistin concentration was a risk factor for ischemic
stroke, especially lacunar and atherothrombotic infarc-
tion, and the association was independent of traditional
confounding factors and hs-CRP. Furthermore, the com-
bination of high resistin concentration and the presence
of either diabetes or hypertension markedly increased the
risk of ischemic stroke. The mechanism by which resistin
induces ischemic stroke in humans and how resistin inter-
acts with diabetes or hypertension to further increase the
risk of ischemic stroke remain unclear. Further studies are
required to clarify these issues.
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